| Literature DB >> 32768570 |
Thangarajeswari Mohan1, Kishore Kumar S Narasimhan2, Divya Bhavani Ravi1, Prema Velusamy1, Navvi Chandrasekar3, Lakshmi Narasimhan Chakrapani1, Ashokkumar Srinivasan1, Porkodi Karthikeyan1, Pugazhendhi Kannan1, Bhavani Tamilarasan1, Thanka Johnson4, Parkavi Kalaiselvan5, Kalaiselvi Periandavan6.
Abstract
Diabetic nephropathy (DN), a progressive kidney disease afflicts more than 20 and up to 40% of the diabetic population and it is characterized by persistent microalbuminuria declined glomerular filtration rate. The interesting feature associated with DN is that, even though the progression of the disease correlates with oxidative stress, Nrf2, the master regulator of antioxidant defense system involved in counteracting oxidative stress is also upregulated in the diabetic kidneys of both human as well as experimental animals in early stages of DN. Despite the increased expression, the ability of this protein to get translocated into the nucleus is diminished signifying the functional impairment of Nrf2, implying redox imbalance. Hence, it is understood that agents that boost the translocation of Nrf2 might be beneficial rather than those that quantitatively overexpress Nrf2 in treating DN. The deleterious effects of synthetic Nrf2 activators have instigated the researchers to search for phytochemicals that have ambient Nrf2 boosting ability with no side effects, one such phytochemical is Epigallocatechin-3-gallate (EGCG) and it has shown beneficial effects by preventing the progression of DN via influencing Nrf2/ARE pathway, however, the modus operandi is unclear, despite speculations. This study was designed to find out whether supplementation of Nrf2 booster like EGCG at the crucial time of Nrf2 dysfunction can mitigate the progression of DN. Based on the findings of the present study, it might be concluded that the beneficial effect of EGCG in mitigating DN is mediated mainly through its ability to activate the Nrf2/ARE signaling pathway at multiple stages i.e., by downregulating Keap1 and boosting the nuclear Nrf2 level by disrupting Nrf2-Keap1 interaction. These results emphasize that supplementation of EGCG might be more beneficial at an early stage of DN, where dysfunctional Nrf2 accumulation occurs, which should be further validated.Entities:
Keywords: Diabetic nephropathy; Epigallocatechin-3-gallate; Nrf2 activator; Nrf2 dysfunction; Oxidative stress
Mesh:
Substances:
Year: 2020 PMID: 32768570 DOI: 10.1016/j.freeradbiomed.2020.07.037
Source DB: PubMed Journal: Free Radic Biol Med ISSN: 0891-5849 Impact factor: 7.376